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Eukaryotic cells counteract oxidative and other envi-
ronmental stress through the activation of Nrf2, the
transcription factor that controls the expression of
a host of protective enzymes by binding to the anti-
oxidant response element (ARE). The electrophilic
molecules that are able to activate Nrf2 and its down-
stream target genes have demonstrated therapeutic
potential in carcinogen-induced tumor models.
Using a high-throughput cellular screen, we discov-
ered a class of ARE activator, which we named
AI-1, that activates Nrf2 by covalently modifying
Keap1, the negative regulator of Nrf2. Biochemical
studies indicated that modification of Cys151 of
Keap1 by AI-1 disrupted the ability of Keap1 to serve
as an adaptor for Cul3-Keap1 ubiquitin ligase com-
plex, thereby causing stabilization and transcrip-
tional activation of Nrf2. AI-1 and its biotinylated
derivative are useful pharmacological probes for
investigating the molecular details of the cellular
antioxidant response.
INTRODUCTION
To survive in an aerobic environment, eukaryotic cells must
protect essential cellular components from oxidative damage
(Halliwell, 2007). The major defensive mechanisms that cells
have developed to counteract oxidative and environmental
stress involve the coordinated up-regulation of a group of
enzymes that detoxify reactive species and restore cellular redox
homeostasis. Classic phase 2 enzymes, such as glutathione
S-transferase (GST) and NAD(P)H:quinone oxidoreductase 1
(NQO1), are an important group of cytoprotective enzymes,
and their induction is controlled at the transcriptional level by
a cis-acting enhancer sequence termed ‘‘antioxidant response
element’’ (ARE) (Kensler et al., 2007; Wang et al., 2007; Wasser-
man and Fahl, 1997). A variety of naturally occurring and
synthetic compounds are believed to mediate their therapeutic
ability to protect against environmental carcinogens, aging,Chemistry & Biology 17,and neurodegeneration by stimulating the ARE pathway (Surh,
2003; van Muiswinkel and Kuiperij, 2005). Here, we report the
discovery of a new class of synthetic, potent, small-molecule
ARE inducer, which we named AI-1, that was identified using a
high-throughput cell-based reporter gene assay. Using a cell-
permeable biotin-derivatized analog and mass spectrometry,
we have discovered that its molecular target is Kelch-like ECH-
associated protein 1 (Keap1). In contrast to known ARE inducers
that are highly reactive (isothiocyanates) or require metabolic
activation (phenols), AI-1 possesses an aromatic chloride that
undergoes a nucleophilic aromatic substitution reaction with
cysteine thiols of Keap1.
Nuclear factor E2–related factor 2 (Nrf2), a Cap ‘n’ Collar (CNC)
type basic region-leucine zipper (bZIP) transcription factor,
binds to the ARE sequence as a heterodimer with one of the
small bZIP proteins, Mafs, and activates ARE-dependent
transcription (Figure 1A). Nrf2 contains six functional domains
that are conserved across species designated Neh1-6 (Nrf2-
ECH homology1–6) domains (Figure 1B). The N-terminal Neh2
domain mediates binding with the cytosolic repressor of Nrf2
(Keap1) (Itoh et al., 1999). Neh4 and Neh5 are transactivation
domains that bind cooperatively to CREB-binding protein (Katoh
et al., 2001). Neh1 domain contains the CNC-type bZIP domain,
enabling Nrf2 to form a heterodimer with the bZIP domain of
small Maf proteins.
Nrf2 is negatively regulated by interaction with the 75 kDa
cysteine-rich protein Keap1 (Dinkova-Kostova et al., 2005;
Kobayashi and Yamamoto, 2006; Zhang, 2006). Keap1 has three
main functional domains: an N-terminal Broad complex, Tram-
track, and Bric-a-brac (BTB) domain; a central intervening region
(IVR); and a series of Kelch repeats located proximal to the C
terminus (Figure 1B). The Kelch domain mediates binding with
the Neh2 domain of Nrf2 (Padmanabhan et al., 2006), whereas
the BTB domain mediates association with ubiquitin E3 ligase
scaffold protein Cullin-3 (Cul3) (Zhang et al., 2004). Keap1 was
initially thought to sequester Nrf2 in the cytoplasm by anchoring
it to the actin cytoskeleton (Itoh et al., 1999). Later, it was found
that Keap1 also functions as an adaptor protein for the
Cul3-based E3 ubiquitin ligase that targets Nrf2 for ubiquitin
conjugation and subsequent proteasomal degradation (Furu-
kawa and Xiong, 2005; Kobayashi et al., 2004; Zhang et al.,
2004). Two evolutionarily conserved motifs within the Neh2
domain (Tong et al., 2006), namely a DLG motif (formulated as537–547, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 537
Figure 1. Current Model of the Keap1/Nrf2/
ARE Pathway
(A) Under normal conditions, Nrf2 is negatively
regulated by the ubiquitination mediated by
Keap1-Cul3 ubiquitin ligase complex and subse-
quent proteasomal degradation. ARE inducers
impair the activity of the Keap1-Cul3 ubiquitin
ligase, and the stabilized Nrf2 translocates into
the nucleus, leading to transcriptional activation
of ARE-driven protective genes.
(B) Domain structures of human Nrf2 and Keap1.
Six conserved Neh1-6 domains are shown in
colors, and DLG and ETGE motifs within Neh2
domain and putative ubiquitin acceptor lysines
are indicated (hNrf2). Locations of all cysteines
and important binding partners are shown, and
three key cysteines (C151, C273, and C288) are
highlighted in red (hKeap1).
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recognized by a Keap1 homodimer, and the multiple lysine resi-
dues located between the twomotifs are targeted for polyubiqui-
tination by the Cul3-Keap1 E3 ligase complex.
In unstressed physiological conditions, Keap1 acts in the
cytoplasm to down-regulate Nrf2’s ability to activate transcrip-
tion. Upon oxidative stress, Nrf2 escapes from Keap1-mediated
repression and translocates to the nucleus, where it induces the
transcription of ARE-directed genes (Figure 1A). Besides oxida-
tive insult induced by radical species, small molecule electro-
philes are also capable of inactivating Keap1 by modifying
several cysteines (Dinkova-Kostova et al., 2002; Wakabayashi
et al., 2004). Among 27 cysteines in human Keap1, three cyste-
ines have been identified to be important modification sites
for the suppression of Keap1. Cell-based mutational studies
(Kobayashi et al., 2006; Zhang and Hannink, 2003) and in vivo
studies (Yamamoto et al., 2008) have revealed that C273 and
C288 in the IVR are required for Keap1-mediated ubiquitination
of Nrf2, whereas C151 located in the BTB domain is required
for Nrf2 to escape from Keap1 in response to ARE inducers.
However, mass spectrometry analysis has detected a number
of reactive cysteines that react with electrophiles (Hong et al.,538 Chemistry & Biology 17, 537–547, May 28, 2010 ª2010 Elsevier Ltd All rights reserved2005; Luo et al., 2007), suggesting that
more cysteine residues may contribute
to modulating Keap1 activity. Here, we
describe mass spectrometry and bio-
chemical analysis of the AI-1–modified
Keap1 and the study on its implication
in the activity of Keap1 and Nrf2.
RESULTS
Discovery of a Small Molecule ARE
Inducer, AI-1
In an effort to discover new ARE inducers
that could be used as chemical tools to
further explore the cellular biology and
physiology of the ARE signaling path-
ways, we performed a high-throughput
cell-based screen for compounds thatare capable of activating the ARE in human neuroblastoma
IMR-32 cells. For a screen of 1.2 million small molecules in
1,536-well format, the top hits (0.5%) were rescreened in tripli-
cate under primary assay conditions and also in the presence
of 1 mM of the antioxidant N-acetylcysteine to exclude hits
arising from induction of oxidative stress. After a triage process
that involved removal of compounds with undesirable functional
groups and predicted nonspecific reactivity, the top 117 com-
pounds were confirmed to the level of dose-response in the
primary assay in 384-well plate format and were tested for the
ARE and NQO1 activity in primary cortical culture (Johnson
et al., 2002). After further prioritization, we identified seven final
lead compounds that are available from commercial sources,
all of which showed a single-digit micromolar potency in the
reporter gene assays (Figure 2A). We chose the chloroquinoli-
none scaffold for further analysis, because this compound did
not appear as electrophilic as some of the other compounds
and exhibited low toxicity. We designated the compound as
AI-1 (ARE Inducer-1; Figure 2B) and demonstrated that it acti-
vates an ARE-dependent luciferase reporter with an EC50 of
2.7 ± 1.6 mM (n = 21) with 70%–80% efficacy compared to our
positive control, tert-butylhydroquinone (tBHQ) (EC50, 5–12 mM)
Figure 2. New Class Synthetic Nrf2/ARE
ActivatorAI-1 and Its Analogs andStructure
and Activity Relationship
(A) Structures of the seven lead ARE inducers
identified from cellular screening of a 1.2 3 106
small-molecule library.
(B) Structures of tBHQ, AI-1, AI-1-Me, AI-1-
amide, and AI-2.
(C) AI-1 induces an hNQO1-ARE-coupled lucif-
erase reporter in IMR-32 cells with a similar
potency to tBHQ, whereas AI-1-Me and AI-1-
amide show no and mild induction, respectively
(left panel). AI-2 shows roughly three times higher
potency than AI-1 in ARE-luc assay (right panel).
Error bars indicate the standard deviations from
triplicate samples.
(D) Summary of the SAR analysis.
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nucleotides (GC) were substituted with AT within the core ARE
sequence, even at a high concentration (30 mM) (see Figure S1
available online), demonstrating that this compound specifically
triggered the ARE response.
Structure and Activity Relationship of AI-1
To investigate structure and activity relationship ofAI-1, a variety
of analogs were synthesized, and their activities were examined
using ARE-luciferase reporter gene assay in IMR-32 cells. AI-1
possesses an electrophilic aryl chloride group located at the
b-position of two a,b-unsaturated carbonyl systems, which
could potentially be displaced by nucleophilic thiols through
a 1,4-addition-elimination reaction. To investigate the functional
requirement of the aryl chloride group for the ability of
compounds to induce the ARE response, we replaced the chloro
substituent with a nonreactive methyl group (AI-1-Me) (Fig-Chemistry & Biology 17, 537–547, May 28, 2010ure 2B). AI-1-Me lost all ability to activate
the ARE up to a concentration of 100 mM
(Figure 2C). We next prepared a number
of analogs where the reactivity of the aryl
chloride group was modulated by intro-
ducing electron donating or withdrawing
functional groups (Figure 2D; Figure S2).
Consistent with previous reports investi-
gating ARE-inducing Michael acceptors
(Dinkova-Kostova et al., 2001; Talalay
et al., 1988), the SAR analysis of AI-1
demonstrated that the electrophilicity
of the reactive chloride determines the
potency of the compounds. For example,
the replacement of esters with ketones
was tolerated, but replacement with am-
ides or other less electron-withdrawing
groups resulted in a significant reduction
in the ARE-inducing activity. The amide
analog of AI-1, AI-1-amide (Figure 2B)
possessed 10% of the ARE-inducing
activity of AI-1 at a concentration of
100 mM (Figure 2C). Interestingly, an ana-
log where the ester of AI-1 was replacedwith a strongly electron-withdrawing nitro group was only
marginally active (compound 4b) (Figure S2). This finding indi-
cates that the reactivity of the halide group is not the sole deter-
minant of activity and that other factors such as intracellular drug
concentration and noncovalent recognition by intracellular target
proteins may also be important. In addition, the SAR analysis
also revealed that the carbonyl at C2 makes a significant con-
tribution to the activity. Modifications of the sites that are located
away from the reactive aryl chloride, such as the ethyl group
of the ester and the methyl at N1, were tolerated. Similarly,
modifications of C7 and C8 positions of the aromatic ring caused
no major loss of activity, suggesting that these positions
do not directly interact with the intracellular target protein.
Through this analysis, we identified an active compound, AI-2
(Figure 2B), that exhibited roughly three-fold more potent ARE-
luc activity relative to AI-1 (EC50, 0.5–2.0 mMwith 140% efficacy;
Figure 2C). Because AI-2 was identified later, most of theª2010 Elsevier Ltd All rights reserved 539
Figure 3. AI-1 Induces Stabilization/
Nuclear Translocation of Nrf2 and Produc-
tion of Downstream protective Genes
Panels show comparison of AI-1 and its analogs
with regard to their effects on the activity of Nrf2
and the expression of NQO1 in IMR-32 cells.
(A) Western blot analysis after 18 hr treatment
showed that AI-1 induces Nrf2 activation and
NQO1 expression in a dose-dependent manner
starting at 1 mM, whereas AI-1-amide has an
effect only at 100 mM and AI-1-Me has no effect
up to 100 mM.
(B) Dose-response analysis after 24 hr treatment
indicated that AI-2 is active at approximately
10-fold lower concentrations than AI-1 with
respect to Nrf2 activation and NQO1 expression.
(C) After treatment with 30 mM AI-1, Nrf2 stabiliza-
tion/nuclear translocation initiated within 1 hr and
reached a plateau after 3 hr. NQO1 expression
appeared after 12 hr and continues to increase.
(D) IMR-32 cells pretreated with either tBHQ or
AI-1 (10 mM) for 48 hr became resistant to cell
death induced by 1 hr treatment of H2O2. Error
bars indicate the standard deviations from
quadruplicate samples.
(E) Cotreatment with inhibitors of either MEK1
(PD098059, 10 mM) or PI3K (LY294002, 25 mM)
for 24 hr followed byWestern blot analysis of cyto-
solic and nuclear fractions revealed that PI3K
activity is required for AI-1 to both stabilize Nrf2
in cytosol and translocate Nrf2 into the nucleus.
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compound AI-1.
AI-1 Stabilizes Nrf2 and Induces Expression
of Protective Enzymes
We investigated the ability of AI-1, AI-1-Me, AI-1-amide, and
Al-2 to stabilize Nrf2 and induce NQO1 expression in IMR-32
cells by measuring protein levels after treatment with various
concentrations of the compounds for 18 hr (Figure 3A). AI-1
was capable of inducing a dose-dependent increase of the levels
of Nrf2 and NQO1, starting at a concentration of 1 mM, whereas
AI-1-amide showed a substantial induction only at a concentra-
tion of 100 mM, and AI-1-Me showed no activation even at
100 mM. From a dose-response analysis after a 24 hr treatment,
AI-2 exhibited approximately 10-fold higher potency in Nrf2
activation and expression of NQO1 relative to AI-1 (Figure 3B).
A time-course study with AI-1 (30 mM) demonstrated that both
stabilization and nuclear translocation of Nrf2 began within 1 hr
and reached a plateau after 3 hr (Figure 3C). Expression of
NQO1 was delayed and only appeared after 12 hr of treatment
and then continued to increase. Notably, a slightly higher molec-
ular weight band of Nrf2 was detected specifically in the nuclear
fraction, which may correspond to phosphorylated Nrf2 local-
ized in nucleus, as reported elsewhere (Apopa et al., 2008).
To investigate whether AI-1 induces oxidative stress, which
thenmight result in ARE activation, IMR-32 cells were pretreated
with 1mMN-acetylcysteine for 2 hr that prevented production of
oxygen free radicals prior to treatment with AI-1 for 24 hr
(Figure S3). The levels of Nrf2 activation and NQO1 expression
induced by tBHQ or AI-1 (20 mM) were not reduced by pretreat-540 Chemistry & Biology 17, 537–547, May 28, 2010 ª2010 Elsevierment of 1 mM N-acetylcysteine, showing that oxidative stress is
not involved in AI-1–mediated ARE activation in IMR-32 cells
(Lee et al., 2001b).
To examine thecytoprotective effect ofAI-1, IMR-32cellswere
pretreatedwith 10 mMof eitherAI-1or tBHQ for 48 hr, followedby
exposure to hydrogen peroxide (200800 mM) for 1 hr, and
viability was determined using an MTT assay (n = 4) (Figure 3D)
(Li et al., 2002).AI-1 and tBHQexhibited similar protective effects
against H2O2-induced apoptosis relative to the DMSO control.
The degree of protection increased both with the time the cells
were exposed to the ARE inducers and the concentration of
H2O2. Although both tBHQ and AI-1 protected cells against the
acute toxicity generated by H2O2, unlike tBHQ, AI-1 did not act
as a free radical scavenger in vitro, as assessed by antioxidant
capacity assays employing ABTS (2,20-azino-bis(3-ethylbenzo-
thiazoline-6-sulfonic acid) and DPPH (2,2-diphenyl-1-picrylhy-
drazyl) (Figure S4). These results are consistent with a model
where the protective effect of AI-1 against oxidative stress is
mediated by Nrf2-mediated antioxidant response, not by radical
scavenging properties.
AI-1-Mediated ARE Activation Is Dependent
on PI3K Activity
The activities of several kinases, including MAPK, PI3K, PKC,
CK2, and PERK, are implicated in the regulation of Nrf2 activity
(Sherratt et al., 2004). It has been also shown that Nrf2 is a direct
substrate of kinases such as PKC (Huang et al., 2002), CK2
(Apopa et al., 2008), and PERK (Cullinan et al., 2003) in vitro, sug-
gesting that phosphorylation events may play an important role
in regulating the activity of Nrf2. However, the kinases involvedLtd All rights reserved
Figure 4. AI-1 Forms a Covalent Bond with
Keap1 in Cells
(A) Chemical structures of AI-1-biotin, AI-1-Me-
biotin, AI-1-amide-biotin, and IAB (upper panel).
AI-1-biotin and AI-1-Me-biotin show similar
activities relative to their parent compounds in
ARE-luc assay using IMR-32 cells (lower panel).
Error bars indicate the standard deviations from
triplicate samples.
(B) Keap1-CBD transfected HEK293 cells were
treated with the biotinylated compounds (50 mM)
and biotin labeling of Keap1 was analyzed with
streptavidin pull-down/CBD blot and chitin pull-
down/streptavidin-HRP blot. The following order
of reactivity toward Keap1 was determined:
AI-1-biotin / AI-1-amide-biotin / AI-1-Me-
biotin.
(C) AI-1, AI-2 (20, 100 mM) were pretreated for 1 hr
before treatment of AI-1-biotin (20 mM) for 3 hr.
Chitin pull-down followed by streptavidin-HRP
analysis indicated thatAI-2 alkylates Keap1 cyste-
inesmore vividly thanAI-1. The band intensity was
quantified using ImageJ software and biotin-
labeled Keap1 was assessed by the intensity ratio
of streptavidin/CBD relative to the ratio from the
DMSO control.
(D) A similar labeling experiment with three
different Keap1 cysteine mutants revealed that
AI-1-biotin alkylates C151 primarily, and alkylates
C273 and C288 to a lesser extent in cells.
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dependent. It has been reported that ARE activation by tBHQ
is dependent on the activity of PI3K, but not ERK, in IMR-32 cells
(Lee et al., 2001a).To investigate whether the PI3K or MAPK
pathway is required for AI-1 to activate the ARE, IMR-32 cells
were cotreated with AI-1 and an inhibitor of either MEK1
(PD098059) or PI3K (LY294002) for 24 hr, and then cytosolic
and nuclear fractions were analyzed. LY294002 (25 mM) but
not PD098059 (10 mM) was capable of blocking Nrf2 stabilization
and nuclear translocation andNQO1 expression induced byAI-1
(10 mM) (Figure 3E). This finding suggests that PI3K activity is
required for AI-1 to both stabilize and translocate Nrf2 into
nucleus.
AI-1 Irreversibly Labels Keap1 Primarily Through
Reaction with Cys151 of Keap1
ARE-inducing activity has been detected from a variety of
compounds, including natural products, compounds derived
from a normal diet, synthetic drugs (Habeos et al., 2008), and
metabolites (Surh, 1999). All reported small molecule ARE
inducers contain thiol-reactive electrophilic centers that cova-Chemistry & Biology 17, 537–547, May 28, 2010lently modify the cysteine thiols of
Keap1 and other thiol-containing
proteins. In analogy to known ARE activa-
tors, we hypothesized that the chloro
substituent of AI-1 might react with one
of the nucleophilic cysteines of Keap1.
The reactive cysteines of Keap1 have
been mapped using biotin-tagged elec-
trophiles, such as iodoacetamide and N-alkylmaleimide, as labeling probes (Hong et al., 2005), but there
are no reports of biotin-probes derivatized from well-character-
ized ARE inducers such as tBHQ (Gharavi et al., 2007) and sulfor-
aphane (Juge et al., 2007). We therefore synthesized three bioti-
nylated compounds where a linker was attached to the
quinolinone nitrogen—a position we had previously demon-
strated to tolerate a variety of functional groups without loss of
ARE-inducing activity (AI-1-biotin, AI-1-Me-biotin, and AI-1-
amide-biotin; Figure 4A). We used the ARE-luc reporter gene
assay using IMR-32 cells to confirm that the biotinylated
compounds were cell permeable and exhibited activity similar
to that of their parent compounds. To investigate whether the bi-
otinylated compounds could covalently modify Keap1, HEK293
cells were transfected with chitin-binding domain (CBD)–tagged
wild-type (WT) Keap1 and treated with the biotinylated
compounds at a concentration of 50 mM for 3 hr. As a positive
control, a known Keap1-alkylating agent N-iodoacetyl-N-bioti-
nylhexylenediamine (IAB, 50 mM; Figure 4A) was included
(Hong et al., 2005). Pull-down with streptavidin beads and
subsequent Western blot analysis using anti-CBD antibody
showed high Keap1 alkylation by AI-1-biotin, modest alkylationª2010 Elsevier Ltd All rights reserved 541
Figure 5. Cys151 of Keap1 Is Determined to Be the Major Site of Modification by AI-1 from Mass Spectrometry Analysis
(A) LC/MS/MS analysis of a chymotryptic digest (amino acid 142–154) following in vitro labeling of Keap1 with AI-1 confirmed alkylation of Cys151 by AI-1.
(B and C) The signals of the unmodified (B) chymotryptic and (C) tryptic peptides that contain Cys151 measured on LTQ IonTrap were decreased by reaction
with AI-1. The LC peaks for the peptides are highlighted in gray.
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Similarly, pull-down with chitin beads followed by streptavidin-
HRP blot analysis also showed the same order of alkylation
levels: AI-1-biotin / AI-1-amide-biotin / AI-1-Me-biotin
(Figure 4B).
AI-2 exhibited stronger ARE-inducing activity relative to AI-1,
despite both compounds being predicted to possess electro-
philic centers of comparable reactivity (Figures 2C and 3B).
To investigate the molecular basis for this observation, we
performed a comparative analysis of the reactivity of AI-1 and
AI-2 toward Keap1 using AI-1-biotin as a means to quantify
the extent of Keap1 labeling. HEK293 cells transfected with
Keap1-CBD were treated with either AI-1 or AI-2 (20 and
100 mM, respectively) for 1 hr, followed by a washout and treat-
ment with AI-1-biotin (20 mM) for another 3 hr. Chitin pull-down
and subsequent analysis of biotinylated Keap1 revealed that
AI-2 masked Keap1 cysteines from being alkylated by AI-1-542 Chemistry & Biology 17, 537–547, May 28, 2010 ª2010 Elsevierbiotin to a greater extent than AI-1 did (Figure 4C). This finding
indicates that AI-2 is more potent than AI-1 in reacting with
Keap1 and provides a potential explanation for its more potent
ARE-inducing activity.
To identify which cysteines of Keap1 were alkylated, HEK293
cells were transfected with CBD-tagged Keap1 WT or mutants
inwhich each of three preferred alkylating cysteineswas replaced
by serine (C151S, C273S, and C288S) and treated with 20 mM of
the two biotin probes (AI-1-biotin or AI-1-Me-biotin) for 3 hr.
Biotin-conjugated protein complexes were pulled down by strep-
tavidin beads and subjected to immunoblot analysis with anti-
CBD antibody. Interestingly, each mutant resulted in a different
degree of alkylation. Alkylation was slightly reduced in the
C273S mutant, more significantly reduced in the C288S mutant,
andalmostcompletelyeliminated in theC151Smutant. Theextent
of labeling event was also proportional to the intensity of high-
molecular-weightKeap1 (HMWKeap1) thatwas formedasa resultLtd All rights reserved
Figure 6. AI-1 Inhibits Keap1-Mediated
Neh2 Ubiquitination In Vivo in a C151-
Dependent Manner
(A and B) HEK293 cells were transiently trans-
fected with Keap1, Gal4-Neh2, and HA-Ub and
treated with tBHQ, AI-1, AI-1-Me, or AI-1-amide
(30 mM) for 5 hr. Lysates were immunoprecipitated
by anti-Gal4 antibody, and ubiquitination was
assessed using anti-HA antibody.
(A) Both tBHQ and AI-1 strongly inhibit Keap1-
mediated Neh2 ubiquitination, whereas AI-1-Me
and AI-1-amide show no and slight inhibition,
respectively (left blot). Treatment with LY294002
(25 mM) does not reverse the inhibitory effect of
tBHQ or AI-1 on Neh2 ubiquitination (right blot).
(B) Neither tBHQ nor AI-1 inhibits Neh2 ubiquitina-
tion in Keap1 C151S mutant-transfected cells.
(C) HEK293 cells were transiently transfected
with Keap1-CBD and HA-Ub and treated with
tBHQ, AI-1 (50 mM) for 12 hr. Immunoprecipitation
with anti-Keap1 antibody and immunoblot with
anti-HA antibody revealed that AI-1 induces
Keap1 ubiquitination in vivo to a smaller extent
relative to tBHQ.
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results is that alkylation of WT Keap1 by AI-1 in cells occurs
primarily on Cys151 in the BTB domain, with some alkylation on
Cys288andonlyminor alkylationonCys273 in the IVR (Figure 4D).
We also conducted an unbiased analysis to discover more
cysteine residuesmodified byAI-1 in vitro.We expressed human
Keap1 in Escherichia coli and incubated the recombinant Keap1
withAI-1 (protein-to-compoundmolar ratio, 1:2) for MS analysis.
Liquid chromatography coupled with tandem mass spectrom-
etry (LC/MS/MS) analysis of the chymotryptic peptide coveringChemistry & Biology 17, 537–547, May 28, 2010Cys151 (amino acid 142–154) showed
an increase of 229 in mass from all
peptide fragments containing Cys151,
indicating that Cys151 was alkylated by
AI-1 (Figure 5A). It was also confirmed
by LC/MS results that the MS signals of
the chymotryptic and tryptic peptide con-
taining Cys151 were diminished by the
reaction with AI-1, whereas no change
was observed by the addition of AI-1-
Me (Figures 5B and 5C). In addition to
C151, covalent modifications at C23,
C38, and C196 were also detected from
LC/MS/MS analysis, albeit with less
intensity (Table S1). Modification of these




We next determined whether treatment
of cells with AI-1 would inhibit Keap1-
mediated Nrf2 ubiquitination. HEK293
cells were cotransfected with expression
vectors for hemagglutinin-ubiquitin (HA-Ub), Gal4-fused Neh2 (amino acid 1–97 of Nrf2), and Keap1,
and treated with 30 mM of each compound for 5 hr. Cell lysates
were immunoprecipitated by anti-Gal4 antibody, and the immu-
nopurified Neh2 domain was analyzed for the presence of ubiq-
uitin byWestern blot analysis using anti-HA antibody (Figure 6A).
Both tBHQ and AI-1 strongly inhibited Keap1-dependent Neh2
ubiquitination. AI-1-amide slightly inhibited the ubiquitination
event, whereas AI-1-Me showed no inhibition. The inhibitory
activity of each compound on Neh2 ubiquitination is well corre-
lated with the effects on other molecular events associatedª2010 Elsevier Ltd All rights reserved 543
Figure 7. AI-1Disrupts Keap1-Cul3 Interac-
tion in a C151-Dependent Manner
(A and B) HEK293 cells were transiently trans-
fected with Gal4-Neh2 andWTKeap1, and treated
with compounds at (A) 30 mM or (B) 50 mM for 5 hr.
The lysates were immunoprecipitated using an
anti-Gal4 antibody, and the level of copurified
Keap1 was measured.
(A) Copurification of Keap1 was not affected by
treatment with the compounds that possessed
different electrophilicity.
(B) Treatment with biotin probes did not change
the binding affinity between Keap1 and Neh2
domain, although the copurified Keap1 was
labeled with biotin to a different extent.
(C) HEK293 cells were transiently transfected with
HA-Cul3 and CBD-tagged WT (or C151S) Keap1,
and treated with tBHQ or AI-1 (30 mM) for 5 hr.
Pull-down using chitin beads and ensuing immu-
noblot analysis with anti-HA antibody showed
that both tBHQ andAI-1 destabilize the interaction
between Keap1 and Cul3 in HEK293 cells in
a C151-dependent manner.
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translocation, Keap1 alkylation, and ARE-luc induction. Neither
tBHQ nor AI-1 was able to protect Nrf2 from ubiquitination in
cells expressing the C151S-Keap1mutant (Figure 6B), indicating
that AI-1 inhibits Keap1-driven ubiquitination of Nrf2 in a C151-
dependent manner.
We then investigated how the PI3K pathway is involved in
regulation of Nrf2. We performed the in vivo Neh2 ubiquitination
assay following treatment of 30 mMof ARE inducers and 25 mMof
LY294002 for 5 hr (Figure 6A). Interestingly, the PI3K inhibitor
did not override the inhibitory effect of tBHQ or AI-1 on Neh2
ubiquitination, although it did down-regulate the endogenous
Nrf2 activated by either ARE inducer. In addition, this PI3K-inde-
pendent regime was also observed for the ubiquitination of both
endogenous and overexpressed full-length Nrf2 in HEK293 cells
(Figures S5A and S5B). These results suggest that phosphoryla-
tion of Nrf2 by kinases located downstream of PI3K may be
involved in the regulation after Nrf2 is relieved from Keap1-medi-
ated down-regulation. We next investigated whether the PI3K
pathway might modulate Nrf2 at the translation level. We exam-
ined the synthesis of endogenous Nrf2 using a 35S-labeling
assay. HEK293 cells were treated with AI-1 (30 mM) together
with LY294002 (20 mM) for 4 hr and were exposed to 35S-methi-
onine/35S-cysteine containing media for 45 min (Figure S5C).
Immunoprecipitation and analysis of 35S-labeled Nrf2 demon-
strated that treatment of LY294002 down-regulates the transla-
tion of basal and induced Nrf2. Together these results indicate
that PI3K signaling modulates Nrf2 at the level of protein transla-
tion rather than protein stability.
Keap1-alkylating ARE inducers, such as tBHQ and sulfora-
phane, elicit autoubiquitination of Keap1, although its biological
implication is unclear. It has been proposed that alkylation of
Keap1 by electrophiles switches the ubiquitination target from
Nrf2 to Keap1 (Hong et al., 2005; Zhang et al., 2005). To see
whether AI-1 also causes Keap1 ubiquitination, Keap1 ubiquiti-
nation was examined following treatment of either tBHQ or
AI-1 (50 mM) for 12 hr to HEK293 cells that were transiently trans-
fectedwith Keap1 andHA-Ub (Figure 6C). Interestingly, although544 Chemistry & Biology 17, 537–547, May 28, 2010 ª2010 ElseviertBHQ and AI-1 showed a similar potency in inhibition of Keap1-
mediated Nrf2 ubiquitination, AI-1 induced Keap1 autoubiquiti-
nation to a smaller extent than tBHQ. which suggests that
tBHQ and AI-1 interact with Keap1 cysteines in different modes
to repress the function of Keap1.
AI-1 Inhibits Nrf2 Ubiquitination by Disrupting
the Interaction Between Cul3 and Keap1
We next investigated the ability of AI-1 to influence the associa-
tion of Keap1 with Nrf2. HEK293 cells were transfected with
expression vectors for Gal4-Neh2 and WT Keap1 and treated
with AI-1 and its analogs (30 mM) for 5 hr. The level of copurified
Keap1was analyzed byWestern blot analysis following immuno-
precipitation with anti-Gal4 antibody (Figure 7A). The level of
copurified Keap1 was not changed by treatment of either com-
pound. In a second experiment, the cotransfected HEK293 cells
were treated with biotinylated compounds (AI-1-biotin, AI-1-
Me-biotin, and AI-1-amide-biotin, 50 mM) for 5 hr, and cell
lysates were immunoprecipitated with anti-Gal4 antibody (Fig-
ure 7B). Western blot analysis with anti-Keap1 antibody showed
that Keap1 copurification was not affected by the treatment with
the biotinylated compounds, although the copurified Keap1 was
biotin-labeled to a different extent, as shown by streptavidin-
HRP blot analysis. Together, these results suggest that alkylation
by AI-1 did not cause dissociation of the Nrf2-Keap1 complex.
Evidence demonstrated that alkylation of Keap1 by electro-
philes promotes the dissociation of the Keap1-Cul3 interaction,
leading to Nrf2 stabilization (Gao et al., 2007; Kobayashi et al.,
2006; Zhang et al., 2004). To investigate whether this is also
observed for AI-1, HEK293 cells were cotransfected with plas-
mids encoding HA-Cul3 and Keap1-CBD and were exposed to
tBHQ and AI-1 (30 mM) for 5 hr. Pull-down with chitin beads fol-
lowed by immunoblot with anti-HA antibody revealed that both
AI-1 and tBHQ caused dissociation of the Keap1-Cul3 interac-
tion (Figure 7C). The disruption of the Keap1-Cul3 interaction
was not observed when the C151S Keap1 mutant was used
instead. This result demonstrates that the alkylation of Keap1
C151 by AI-1 is required for dissociation of the Keap1-Cul3Ltd All rights reserved
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activation of the ARE pathway. Although both tBHQ and AI-1
generated HMW Keap1 as a result of covalent reaction, AI-1
produced HMW Keap1 to a much smaller extent than a
phenolic antioxidant tBHQ. The similar potency of tBHQ and
AI-1 to impair the Keap1-Cul3 interaction indicates that the
formation of the HMW Keap1 does not cause the Keap1-Cul3
dissociation.
We also compared AI-1 and AI-2with respect to their ability to
disrupt the Keap1-Cul3 interaction (Figure S6). Dose-response
analysis revealed that AI-2 is slightly more potent to disrupt
the Keap1-Cul3 interaction than AI-1. These studies suggest
a model whereby the stronger Nrf2/ARE-inducing activity of
AI-2 (Figures 2C and 3B) can be explained by more rapid
Keap1 alkylation (Figure 4C), which causes more efficient disso-
ciation of Keap1 from Cul3 (Figure S6). Further investigation will
be required to determine whether AI-2 is simply accumulated in
cells to a greater extent than AI-1 or whether it possesses supe-
rior noncovalent interaction with Keap1 that predisposes it to
more efficient covalent bond formation.
AI-1 Reacts with a Number
of Intracellular Proteins
We attempted to identify other intracellular targets of AI-1
using the AI-1-biotin probe in conjunction with mass spectrom-
etry. AI-1-biotin and AI-1-Me-biotin (50 mM) were treated to
HEK293 cells, and biotin-labeled proteins were pulled down
using streptavidin beads (Figure S7A). The specific band at 65
kDa from AI-1-biotin and the equivalent bands from DMSO
and AI-1-Me-biotin that served as negative controls were sub-
jected to LC/MS/MS analysis. The list of AI-1-specific binding
proteins was obtained after the proteins detected from either
negative control were subtracted (Figure S7B and Table S2).
Among the AI-1-specific proteins, reactive cysteine-containing
enzymes such as phosphatase (PP2A) and cysteine-rich ubiqui-
tin E3 ligase (ARIH1) were identified, illustrating the ability of AI-1
to target cysteines in various classes of proteins. Interestingly,
histone deacetylase1/2 (HDAC1/2) was identified as binding
proteins. In analogy to the proposedmechanism of HDAC inhibi-
tion by an ARE inducer sulforaphane (Myzak et al., 2004, 2006),
a metabolic product of AI-1, as a result of its covalent reaction
with intracellular cysteine, may also be able to inhibit HDAC1/2
and evoke the related biological effects. A subset of the identi-
fied proteins could be related to Nrf2/ARE pathway, but we think
that Keap1-alkylation is sufficient to account for the ARE-
inducing activity of AI-1 because of the ability of the Keap1
C151S mutant to induce resistance to the compound. In-depth
molecular analysis about whether any of these additional tar-
gets are involved in Keap1/Nrf2 regulation is currently under
investigation.
DISCUSSION
The activation of the Nrf2-ARE pathway is initiated by covalent
modifications of cysteine thiols of Keap1 by electrophiles, radi-
cals, or heavy metals. Although all of these species are destined
to enhance transcriptional activity of Nrf2, the detailed mecha-
nisms by which these species suppress the activity of Keap1
are not the same. For example, studies have shown thatChemistry & Biology 17,Keap1 modification by electrophiles, such as tBHQ and sulfora-
phane, dissociates the Keap1-Cul3 interaction in a C151-depen-
dent manner, whereas some heavy metals, such as arsenic
species, promote the association of the two proteins in a
C151-independent fashion (Wang et al., 2008). There might be
more mechanisms yet for sensing thiol-reacting agents and
perturbing Keap1 activity that are required for Nrf2-driven anti-
oxidant response.
In this paper, we reported the discovery and characterization
of a new class of small-molecule ARE inducer, AI-1. AI-1 bears
a reactive chloride that is located at the 4-position of two
a,b-unsaturated carbonyl systems and that undergoes a nucle-
ophilic aromatic substitution reaction with Keap1 cysteines.
AI-1 activates the Nrf2-ARE pathway, induces expression of
antioxidant proteins such as NQO1, and increases cell survival
in the condition of H2O2-induced oxidative stress. Functional
analysis of AI-1 and related analogs that exhibit a broad range
of the electrophilicity revealed that the key target protein of
AI-1 is Keap1 and that the electrophilicity of the compound
is necessary for its activity. As seen with tBHQ and sulfora-
phane, the formation of a covalent bond with Cys151 of
Keap1 was the most important event underlying AI-1–driven
Nrf2-ARE activation.
A unique and advantageous characteristic of AI-1, rarely seen
from other ARE inducers, is the ease with which ARE-inducing
activity can bemodulated by altering electrophilicity or noncova-
lent recognition features of the scaffold. As a result, wewere able
to interrogate the extensive SAR analysis and obtainmore potent
analogs such as AI-2. The discovery of AI-2, whose electrophi-
licity should be similar to that of AI-1, suggests that noncovalent
recognition of the small molecule by Keap1 may also be a signif-
icant contributor to the potency and efficacy of ARE-inducing
small molecules. The SAR also revealed that the size of the
substitutent at the C4 position was crucial for recognition by
Keap1. For example, the chloride of AI-1 could be replaced by
a bromide but not by a larger tosyl group (compound 1d)
(Figure S2).
The SAR analysis enabled us to derivatize AI-1 with a linker
without losing ARE-inducing activity, leading to the synthesis of
a nontoxic, cell-permeable biotinylated compound, AI-1-biotin.
It served as a valuable probe to investigate the consequences of
alkylating Keap1. We exploited AI-1-biotin to assess the relative
reactivity of three important Keap1 cysteines (C151, C273, and
C288) in cells and determined that C151 is the most reactive
nucleophile toward AI-1. Further study will be required to inves-
tigate how reaction with the reactive C151 regulates Keap1
activity. It has been proposed that C151 alkylation might induce
a conformational change of Keap1 to expose the two additional
cysteines, C273 and C288, located in the IVR for alkylation
(Zhang and Hannink, 2003). It may be also possible that cooper-
ativemodifications at C151 andC273/C288 byAI-1might lead to
the inhibition of Keap1-mediated Nrf2 ubiquitination.
The detailed SAR of AI-1 shown in this article may provide
insight for designing ARE inducers. As demonstrated by AI-2,
further medicinal chemistry efforts on AI-1 or other lead com-
pounds could lead to discovery of more powerful ARE inducers.
AI-1 and analogs may also find utility in exploring the therapeutic
benefits of ARE activators in animal models of conditions where
oxidative stress is implicated (Klaunig and Kamendulis, 2004).537–547, May 28, 2010 ª2010 Elsevier Ltd All rights reserved 545
Chemistry & Biology
Small-Molecule Inducer of Antioxidant ResponseSIGNIFICANCE
The Keap1-Nrf2-antioxidant response element (ARE) path-
way is the major signaling pathway for sensing oxidative
and environmental stress and for inducing a protective
cellular response. Several electrophilic small molecules
that stimulate this pathway have been reported to possess
therapeutic benefit under stress-related conditions, such
as neurodegeneration and carcinogenesis, owing to their
ability to induce the expression of a wide range of protective
proteins. Besides the utility in therapeutics, small-molecule
ARE inducers can be pharmacological tools of the cellular
antioxidant response. Here, we reported the discovery of
a novel quinolinone-based ARE inducer (AI-1) that was iden-
tified from unbiased high-throughput screening of a small-
molecule library. AI-1 is the first ARE inducer that is sensed
by the cysteines of intracellular redox sensor Keap1 through
a nucleophilic aromatic substitution reaction. On the basis
of the effects on Keap1, such as formation of a high-molec-
ular-weight Keap1 and autoubiquitination, AI-1 is function-
ally similar to sulforaphane rather than tBHQ. However,
unlike sulforaphane, the chemical, structural feature of
AI-1 allows the generation of a wide range of functional
analogs. The SAR analysis revealed that both the reactivity
of the electrophilic site and the noncovalent recognition
features of the compound control the potency of the com-
pound. Our study revealed that Cys151 is the most reactive
residue toward AI-1 among the 27 cysteines of human
Keap1 and that covalent modification of Cys151 disrupted
the ability of Keap1 to serve as an adaptor for Cul3-ubiquitin
E3 ligase complex, thereby leading to AI-1-driven Nrf2 acti-
vation. The mechanism of the Nrf2/ARE activation and the
mode of interaction with Keap1, as demonstrated with AI-1,
are likely to be applicable to other classes of cysteine-
reactive small molecules.
EXPERIMENTAL PROCEDURES
ARE-Luciferase Reporter Gene Assay
hNQO1-ARE-luc reporter gene constructs (Moehlenkamp and Johnson, 1999)
used for cell-based reporter gene assay were provided by Dr. Jeffrey Johnson
(University of Wisconsin, Madison), and the sequence information of both WT
and mutant ARE-luc is described in literature (Lee et al., 2001b) and in
Figure S1. ARE-luc construct (100 ng/well) was transiently transfected to
IMR-32 cells (10,000 cells, 60 mL/well) in white 384-well plates (Corning) using
Fugene6 (Roche) following themanufacturer’s procedure. After 24 hr transfec-
tion, preplated compounds that were prediluted into dose-response format
(three-fold dilution, 12 points) ranging from 10 mM were transferred (600 nL)
to the assay plates using a 384-pin transfer device. Each concentration was
tested in triplicate. After 24 hr incubation in a cell incubator, BrightGlo
(30 mL, Promega) was added and luminescence was quantified by using
Envision multilabel plate reader (PerkinElmer). EC50 values were calculated
using GraphPad Prism 4 (GraphPad Software). For the test of compounds in
the presence of 1 mM N-acetylcysteine, cells (50 mL/well) were transfected
for 24 hr and treated with 10 ml of 6 mM N-acetylcysteine in cell media
(pH 7.4) for 2 hr prior to compound addition.
In Vivo Ubiquitination Assay
In vivo ubiquitination assay was performed as reported elsewhere (Busch-
mann et al., 2000) with a minor modification. HEK293 cells in a six-well plate
were transfected with cDNAs encoding Keap1, Gal4-tagged Neh2 (or
HA-tagged Nrf2), and HA-tagged ubiquitin. After washing with cold PBS, cells546 Chemistry & Biology 17, 537–547, May 28, 2010 ª2010 Elsevierwere lysed with 2%SDS in TBS (10mM Tris-HCl [pH 8.0] and 150mMNaCl) at
95

C for 10 min and were sonicated for 20 s at 4

C. Eight volumes of 1% Triton
X-100 in TBS were added, and the solution was incubated for 30 min at 4

C
with Protein G beads (Roche) and clarified by 1 min centrifugation (20,000 g)
at 4

C. The protein solution (supernatant) was incubated with anti-Gal4 anti-
body (Santa Cruz Biotechnology) for 1 hr at 4

C before overnight incubation
with Protein G beads at 4

C. The beads were washed with 0.5 M LiCl in TBS
followed by two additional washes with TBS. Proteins were loaded onto 8%
SDS-PAGE gel, and subjected to immunoblot analysis with anti-HA antibody
(Covance).
For in vivo ubiquitination of endogenous Nrf2, HEK293 cells were seeded in
100-mm dishes and treated with 10 mM MG132, 30 mM LY294002, 30 mM
tBHQ, and 30 mM AI-1 for 4 hr. Cells were lysed with TBS buffer containing
2% SDS, boiled, and sonicated. The resulting lysates were diluted 5 times
with TBS buffer and were then subjected to immunoprecipitation with
anti-Nrf2 antibody (C20, Santa Cruz Biotechnology) and immunoblot with
anti-ubiquitin antibody (s).SUPPLEMENTAL INFORMATION
Supplemental information contains seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.chembiol.2010.03.013.
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